Key facts: Novo Nordisk’s Wegovy launch faces competition; shares drop — TradingView News
Deutsche Bank’s Emmanuel Papadakis highlighted Novo Nordisk’s potential in the obesity market with Wegovy’s strong launch, despite a target price cut. Shares fell 2.4% to 307.55 kroner.1Novo Nordisk plans to expand the distribution of its weight-loss medication Wegovy by introducing vials, enhancing accessibility for consumers.2Novo Nordisk faces heightened competition in the obesity-drug market as Eli Lilly has launched its weight-loss drug Zepbound in 2024, accompanied by a price reduction and expanded online availability.3